{"id":12725,"date":"2025-02-12T08:26:32","date_gmt":"2025-02-12T07:26:32","guid":{"rendered":"https:\/\/resemedicin.se\/reseradet\/?p=12725"},"modified":"2025-02-24T08:27:05","modified_gmt":"2025-02-24T07:27:05","slug":"2025-02-12-forsta-chikungunyavaccinet-ixchiq-tillgangligt-i-sverige","status":"publish","type":"post","link":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-02-12-forsta-chikungunyavaccinet-ixchiq-tillgangligt-i-sverige\/","title":{"rendered":"2025-02-12 F\u00f6rsta Chikungunyavaccinet (IXCHIQ\u00ae) tillg\u00e4ngligt i Sverige"},"content":{"rendered":"\n<p>Vaccinet IXCHIQ\u00ae, det f\u00f6rsta vaccinet mot chikungunyafeber, finns nu tillg\u00e4ngligt i Sverige. Vaccinet \u00e4r sedan tidigare godk\u00e4nt i USA, Kanada, Storbritannien och Europa f\u00f6r vuxna \u00f6ver 18 \u00e5r.\u00a0<\/p>\n\n\n\n<p>I avvaktan p\u00e5 nationella nationella svenska rekommendationer anser&nbsp;<strong>Reser\u00e5det&nbsp;<\/strong>att vaccination med&nbsp;<strong>IXCHIQ\u00ae<\/strong>&nbsp;kan vara motiverat f\u00f6r f\u00f6ljande grupper av resen\u00e4rer (modifierat fr\u00e5n&nbsp;<a href=\"https:\/\/www.cdc.gov\/chikungunya\/hcp\/vaccine\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC:s rekommendationer<\/a>):<\/p>\n\n\n\n<p>A. Land eller omr\u00e5de med&nbsp;<strong>p\u00e5g\u00e5ende<\/strong>&nbsp;chikungunya-utbrott:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rekommenderas till:<\/strong>\u00a0vuxna >18 \u00e5r som vistas >2 veckor p\u00e5 landsbygd, speciellt under regnperioden.<\/li>\n<\/ul>\n\n\n\n<p><strong>B.&nbsp;<\/strong>Land eller omr\u00e5de utan k\u00e4nt p\u00e5g\u00e5ende utbrott men med bevis p\u00e5 \u00f6verf\u00f6ring av chikungunya-virus till m\u00e4nniskor under de&nbsp;<strong>senaste 5 \u00e5ren&nbsp;<\/strong>(s\u00e4rskilt under regns\u00e4songen)<strong>:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>\u00d6verv\u00e4gas till:\u00a0<\/strong>personer\u00a0>65 \u00e5r (l\u00f6per h\u00f6gre risk f\u00f6r l\u00e5ngtidsbesv\u00e4r efter infektion) vid vistelse\u00a0>2 veckor med myggexponering s\u00e4rskilt dem med underliggande kroniska sjukdomar (ej korttidsresen\u00e4rer som huvudsakligen kommer att befinna sig inomhus i luftkonditionerade utrymmen).<\/li>\n\n\n\n<li><strong>\u00d6verv\u00e4gas till:\u00a0<\/strong>personer 18-65 \u00e5r, med underliggande kroniska sjukdomar, vid sammanlagd vistelse\u00a0>3 m\u00e5nader.<\/li>\n\n\n\n<li><strong>\u00d6verv\u00e4gas till:\u00a0<\/strong>personer 18-65 \u00e5r, utan underliggande kroniska sjukdomar, vid sammanlagd vistelse\u00a0>6 m\u00e5nader.<\/li>\n<\/ul>\n\n\n\n<p><strong>C. Land eller omr\u00e5de med tidigare k\u00e4nd chikungunyaf\u00f6rekomst men utan bevis p\u00e5 \u00f6verf\u00f6ring av chikungunya-virus bland m\u00e4nniskor under de senaste 5 \u00e5ren (s\u00e4rskilt under regns\u00e4songen)<\/strong>.<\/p>\n\n\n\n<p>Indikationen f\u00f6r vaccination \u00e4r relativ och b\u00f6r, tills vi har mer erfarenhet, bara \u00f6verv\u00e4gas under speciella individuella omst\u00e4ndigheter<\/p>\n\n\n\n<p><a href=\"https:\/\/resemedicin.se\/reseradet\/vaccination\/ixchiq\/\">L\u00e4s mer om IXCHIQ\u00ae<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/resemedicin.se\/reseradet\/sjukdomar-och-vacciner\/chikungunya\/\">L\u00e4s mer om chikungunyafeber<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vaccinet IXCHIQ\u00ae, det f\u00f6rsta vaccinet mot chikungunyafeber, finns nu tillg\u00e4ngligt i Sverige. Vaccinet \u00e4r sedan tidigare godk\u00e4nt i USA, Kanada, Storbritannien och Europa f\u00f6r vuxna \u00f6ver 18 \u00e5r.\u00a0 I avvaktan p\u00e5 nationella nationella svenska rekommendationer anser&nbsp;Reser\u00e5det&nbsp;att vaccination med&nbsp;IXCHIQ\u00ae&nbsp;kan vara motiverat f\u00f6r f\u00f6ljande grupper av resen\u00e4rer (modifierat fr\u00e5n&nbsp;CDC:s rekommendationer): A. Land eller omr\u00e5de med&nbsp;p\u00e5g\u00e5ende&nbsp;chikungunya-utbrott: B.&nbsp;Land eller &hellip; <a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-02-12-forsta-chikungunyavaccinet-ixchiq-tillgangligt-i-sverige\/\" class=\"more-link\">Forts\u00e4tt l\u00e4sa<span class=\"screen-reader-text\"> \u201d2025-02-12 F\u00f6rsta Chikungunyavaccinet (IXCHIQ\u00ae) tillg\u00e4ngligt i Sverige\u201d<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-12725","post","type-post","status-publish","format-aside","hentry","category-epinytt","post_format-post-format-aside"],"modified_by":"Reser\u00e5det","jetpack_featured_media_url":"","jetpack-related-posts":[{"id":13160,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-08-ema-vaccinera-inte-aldre-over-65-ar-med-ixchiq\/","url_meta":{"origin":12725,"position":0},"title":"2025-05-08 EMA: Vaccinera inte \u00e4ldre \u00f6ver 65 \u00e5r med Ixchiq\u00ae","author":"Reser\u00e5det","date":"2025-05-08","format":"aside","excerpt":"OBS! Rekommendationerna nedan g\u00e4ller inte l\u00e4ngre se uppf\u00f6ljande notis i EpiNytt: 2025-07-13 EMA:s granskning av Ixchiq\u00ae klar. Vaccinet kan \u00e5ter ges till \u00e4ldre >65 \u00e5r. Som EpiNytt tidigare rapporterat har s\u00e4kerhetskommitt\u00e9 vid Europeiska L\u00e4kemedelsmyndigheten (EMA) inlett en granskning av chikungunyavaccinet Ixchiq\u00ae efter rapporter om allvarliga biverkningar hos \u00e4ldre personer. M\u00e5nga\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12947,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-04-28-amerikanska-och-franska-myndigheter-utreder-mojliga-allvarliga-biverkningar-av-ixchiq-hos-aldre\/","url_meta":{"origin":12725,"position":1},"title":"2025-04-28 Amerikanska och franska myndigheter utreder m\u00f6jliga allvarliga biverkningar av Ixchiq\u00ae hos \u00e4ldre","author":"Reser\u00e5det","date":"2025-04-28","format":"aside","excerpt":"Efter rapporterar om allvarliga biverkningar (severe adverse events - SAE) efter vaccination av \u00e4ldre personer med IXCHIQ\u00ae mot chikungunyafeber, har s\u00e5v\u00e4l amerikanska som franska myndigheter nyligen g\u00e5tt ut och f\u00f6rordat tillf\u00e4llig f\u00f6rsiktighet (USA) eller avr\u00e5dan (Frankrike) fr\u00e5n vaccination av personer >65 \u00e5r tills eventuella orsakssamband \u00e4r klargjorda. Under sitt ordinarie\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14383,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-06-19-uppdaterade-rekommendationer-for-vaccination-mot-chikungunyafeber\/","url_meta":{"origin":12725,"position":2},"title":"2025-06-19 Uppdaterade rekommendationer f\u00f6r vaccination mot chikungunyafeber","author":"Reser\u00e5det","date":"2025-06-19","format":"aside","excerpt":"Reser\u00e5det har uppdaterat sina rekommendationer r\u00f6rande vaccination mot chikungunyafeber. Avsikten med denna uppdatering \u00e4r b\u00e5de att f\u00f6renkla beslutet om vaccination och att l\u00e5ta dem vila p\u00e5 b\u00e4sta m\u00f6jliga och regelbundet uppdaterade epidemiologiska data. Riskbed\u00f6mningen bakom de nya rekommendationerna baseras nu p\u00e5 ECDC:s kartor i st\u00e4llet f\u00f6r p\u00e5 fall rapporterade till\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":15097,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-10-22-nya-rekommendationer-fran-silf-om-chikungunyavaccination\/","url_meta":{"origin":12725,"position":3},"title":"2025-10-22 Nya rekommendationer fr\u00e5n SILF om chikungunyavaccination","author":"Reser\u00e5det","date":"2025-10-22","format":"aside","excerpt":"Svenska infektionsl\u00e4karf\u00f6reningens programgrupp f\u00f6r vaccinationer har publicerat en v\u00e4gledning f\u00f6r vaccination mot chikungunyafeber. Nedan f\u00f6ljer rekommendationen i sammandrag: Vaccination rekommenderas till Till personer \u226512 \u00e5r som reser till ett omr\u00e5de med p\u00e5g\u00e5ende utbrott kan Vimkunya rekommenderas. I andra hand kan Ixchiq \u00f6verv\u00e4gas, men Ixchiq b\u00f6r undvikas till personer \u226565 \u00e5r.\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12981,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-03-ema-uppmanar-till-forsiktighet-med-ixchiq-till-aldre-sarskilt-multisjuka-individer\/","url_meta":{"origin":12725,"position":4},"title":"2025-05-03 EMA uppmanar till f\u00f6rsiktighet med Ixchiq\u00ae till \u00e4ldre, s\u00e4rskilt multisjuka individer","author":"Reser\u00e5det","date":"2025-05-03","format":"aside","excerpt":"Som vi tidigare rapporterat, har ett antal sv\u00e5ra m\u00f6jliga biverkningar (severe adverse events - SAE) rapporterats efter vaccination med Ixchiq\u00ae, Valnevas levande f\u00f6rsvagade vaccin mot chikungunyafeber. Med anledning av detta har nu \u00e4ven den europeiska l\u00e4kemedelsmyndigheten EMA g\u00e5tt ut med en uppmaning om att tills vidare \"f\u00f6rsiktighet b\u00f6r iakttas vid\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12765,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-03-08-uppdatering-chikungunyafeber-stora-utbrott-i-reunion-och-brasilien\/","url_meta":{"origin":12725,"position":5},"title":"2025-03-08 Uppdatering chikungunyafeber &#8211; stora utbrott i R\u00e9union och Brasilien","author":"Reser\u00e5det","date":"2025-03-08","format":"aside","excerpt":"ECDC rapporterar att fr\u00e5n \u00e5rets b\u00f6rjan t.o.m. 25 februari, har \u00f6ver 30 000 fall av chikungunyafeber rapporterats fr\u00e5n 14 l\u00e4nder\/territorier. Flest fall under \u00e5ret har rapporterats fr\u00e5n Brasilien (31 484 fall, varav 14 d\u00f6dsfall), Argentina (512 fall), Bolivia (33 fall) och Paraguay (23 fall). Fr\u00e5n Asien har Pakistan rapporterat 201\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/comments?post=12725"}],"version-history":[{"count":1,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12725\/revisions"}],"predecessor-version":[{"id":12726,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12725\/revisions\/12726"}],"wp:attachment":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/media?parent=12725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/categories?post=12725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/tags?post=12725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}